Fig. 2: Limited viral replication in the respiratory tract of pre-immune animals after XBB.1.5 infection.

A Active viral replication of SARS-CoV-2 XBB.1.5 virus in the nasal cavity and lungs (samples collected by nasal swabs and BAL, respectively) assessed by subgenomic (sg)N gene-targeted RT-qPCR (n = 3–12 biological replicates per group). B Peak sgN copies in the upper and lower airways (n = 3–12 biological replicates per group). C Proportion of animals in each group with detectable sgN transcripts in the nasal cavity and/or lungs, or lack thereof, at any point after infection (n = 3–12 biological replicates per group). D Presence of SARS-CoV-2 XBB.1.5 virus in the nasal cavity and lungs (samples collected by nasal swabs and BAL, respectively) assessed by genomic (g)N gene-targeted RT-qPCR (n = 3–12 biological replicates per group). E Peak gN copies in the upper and lower airways (n = 3–12 biological replicates per group). F Proportion of animals in each group with detectable gN transcripts in the nasal cavity and/or lungs, or lack thereof, at any point after infection (n = 3–12 biological replicates per group). Horizontal dotted line represents a lower level of detection (A, B, D, E). Statistical analysis was performed using a non-parametric Kruskal-Wallis test with Dunn’s correction for multiple analysis (B, E). LLOD lower level of detection. Source data are provided as a Source Data file.